NEW YORK (GenomeWeb News) – Vermillion reported after the close of the market on Wednesday that its fourth quarter revenues rose 123 percent, thanks largely to an increase in its average revenue per test, year over year.

The company reported Q4 revenues of $805,000, up from $361,000 in Q4 2015.

Vermillion posted $680,000 in product revenues from sales of its OVA1 ovarian cancer test, and $125,000 in service revenue from its Aspira IVD business. All of Vermillion's revenues in Q4 2015 came from OVA1 sales.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.